| Trial ID: | L6344 |
| Source ID: | NCT00549133
|
| Associated Drug: |
Irbesartan
|
| Title: |
Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
|
| Acronym: |
IREDIS
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Irbesartan
|
| Outcome Measures: |
Primary: Evaluation of the effect of irbesartan on nitric oxide (NO), which has key role in the endothelial dysfunction and the development of pressure vasomotor response, compared to standard therapy (atenolol) | Secondary: Evaluation of the effect of irbesartan on chronic inflammatory process and tendency for procoagulation, associated with endothelial dysfunction, compared to atenolol.
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
44
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-10
|
| Completion Date: |
2005-04
|
| Results First Posted: |
|
| Last Update Posted: |
2007-10-25
|
| Locations: |
Sanofi-Aventis, Istanbul, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT00549133
|
